Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | NNMT | P40261 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 2/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29958137 | 0.98 | ENPP2 (0.37) | ENPP2KDM4EALDH1A1HPGDBTK | |
| Hydrochloric Acid SCHEMBL16180096 | 0.98 | ENPP2 (0.37) | ENPP2KDM4EALDH1A1HPGDBTK | |
| SCHEMBL1843505 | 0.91 | HTR7 (0.41) | ENPP2KDM4EALDH1A1HPGDBTK | |
| SCHEMBL14730091 | 0.86 | BTK (0.37) | ENPP2KDM4EALDH1A1HPGDBTK | |
| SCHEMBL29956176 | 0.79 | MAPK8 (0.49) | ALDH1A1BTKGRM5 | |
| SCHEMBL14582424 | 0.79 | MAPK8 (0.49) | ALDH1A1BTKGRM5 | |
| SCHEMBL29956186 | 0.79 | TRPV3 (0.43) | — | |
| SCHEMBL29958501 | 0.79 | MAPT (0.36) | ALDH1A1POLBGRM5 | |
| SCHEMBL160602 | 0.77 | BTK (0.47) | KDM4EALDH1A1HPGDBTKPOLB | |
| SCHEMBL20067383 | 0.77 | ENPP2 (0.36) | ENPP2KDM4EALDH1A1TDP1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 250 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12421225-B2 | Heteroaromatic amide derivative and medicament containing the same | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2025-09-23 | — | — | US | disclosed |
| US-12404253-B2 | 2,4,6-trisubstituted 1,3,5-triazines as modulators of CX3CR1 | ASTRAZENECA AB (SE) | 2025-09-02 | — | — | US | disclosed |
| US-20250257089-A1 | ORGANOMETALLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO. LTD. (KR) | 2025-08-14 | — | — | US | disclosed |
| EP-3351533-B1 | BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME | KAKEN PHARMA CO LTD (JP) | 2025-07-23 | — | — | EP | disclosed |
| US-12324349-B2 | Organometallic compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2025-06-03 | — | — | US | disclosed |
| CN-120077035-A | As CX32,4, 6-Trisubstituted 1,3, 5-triazines as modulators of CR1 | 阿斯利康(瑞典)有限公司 | 2025-05-30 | — | — | CN | disclosed |
| US-20250145642-A1 | BICYCLIC HETEROARENES AND METHODS OF THEIR USE | Kineta, Inc. | 2025-05-08 | — | — | US | disclosed |
| WO-2025095751-A1 | NOVEL COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER COMPRISING SAME | 현대약품 주식회사 | 2025-05-08 | — | — | WO | disclosed |
| US-20250122172-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE LLC | 2025-04-17 | — | — | US | disclosed |
| US-20250092040-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2025-03-20 | — | — | US | disclosed |
| EP-2004630-A1 | 2-AMINOPYRIMIDIN-4-ONES AND THEIR USE FOR TREATING OR PREVENTING A -RELATED PATHOLOGIES | AstraZeneca AB (SE) | 2008-12-24 | — | — | EP | disclosed |
| EP-1885362-A2 | NOVEL CHEMICAL COMPOUNDS | Smithkline Beecham Corporation (US) | 2008-02-13 | — | — | EP | disclosed |
| US-20080004285-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2008-01-03 | — | — | US | disclosed |
| WO-2007114771-A1 | 2-AMINOPYRIMIDIN-4-ONES AND THEIR USE FOR TREATING OR PREVENTING Aβ-RELATED PATHOLOGIES | ASTRAZENECA AB (SE) | 2007-10-11 | — | — | WO | disclosed |
| EP-1831217-A2 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2007-09-12 | — | — | EP | disclosed |
| US-20070203210-A1 | Thiazolyl-benzimidazoles | BOYLAN JOHN FREDERICK | 2007-08-30 | — | — | US | disclosed |
| US-20070027150-A1 | 2-Amino-quinazolin-5-ones | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070027150-A1 | 2-Amino-quinazolin-5-ones | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2007-02-01 | — | — | US | disclosed |
| WO-2006127458-A2 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006069805-A2 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122172-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4D | ENPP2 3052/4885KDM4E 302/4885ALDH1A1 1288/4885 |
| US-20070203210-A1 | Thiazolyl-benzimidazoles | CYP3A7, CYP2C19, CYP3A5 | ENPP2 4807/4885KDM4E 3163/4885ALDH1A1 100/4885 |
| US-12404253-B2 | 2,4,6-trisubstituted 1,3,5-triazines as modulators of CX3CR1 | CX3CR1, CCR2, CCR5 | ENPP2 1072/4885KDM4E 4608/4885ALDH1A1 1531/4885 |
| US-20080004285-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | PNPO, TYMP, PNP | ENPP2 1571/4885KDM4E 2789/4885ALDH1A1 1225/4885 |
| US-12421225-B2 | Heteroaromatic amide derivative and medicament containing the same | SCN7A, HCN4, SCN4A | ENPP2 1620/4885KDM4E 2231/4885ALDH1A1 1596/4885 |
| US-20250257089-A1 | ORGANOMETALLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | MT-CO1, OXA1L, CRY1 | ENPP2 4800/4885KDM4E 938/4885ALDH1A1 29/4885 |
| US-20250092040-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | ENPP2 1273/4885KDM4E 2376/4885ALDH1A1 4692/4885 |
| US-20070027150-A1 | 2-Amino-quinazolin-5-ones | TK1, TK2, SLC1A5 | ENPP2 1098/4885KDM4E 3934/4885ALDH1A1 1718/4885 |
| US-20250145642-A1 | BICYCLIC HETEROARENES AND METHODS OF THEIR USE | TARDBP, TDP2, PSEN2 | ENPP2 1999/4885KDM4E 2939/4885ALDH1A1 2999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.